Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: UTHR

United Therapeutics Corporation

Healthcare | Biotechnology

Market prices for UTHR are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$27.91

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 16:35 UTC.

What United Therapeutics Corporation does

United Therapeutics is a public benefit corporation founded to develop therapies for serious diseases with unmet medical needs, particularly pulmonary arterial hypertension and rare diseases. The company markets and sells therapies in the United States and other countries, including inhaled, injectable, and oral treatments for pulmonary hypertension conditions, as well as an oncology product for neuroblastoma.

Summarized from United Therapeutics Corporation’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$27.91
Return on equity18.81%

Revenue, margins & earnings

FY2021 Net income: $476MFY2021 Taxes & interest: $80MFY2021 Operating expenses: $1.01BFY2021 Cost of revenue: $122M$1.69BFY2021FY2022 Net income: $727MFY2022 Taxes & interest: $252MFY2022 Operating expenses: $805MFY2022 Cost of revenue: $152M$1.94BFY2022FY2023 Net income: $985MFY2023 Taxes & interest: $200MFY2023 Operating expenses: $885MFY2023 Cost of revenue: $258M$2.33BFY2023FY2024 Net income: $1.20BFY2024 Taxes & interest: $182MFY2024 Operating expenses: $1.19BFY2024 Cost of revenue: $310M$2.88BFY2024FY2025 Net income: $1.33BFY2025 Taxes & interest: $158MFY2025 Operating expenses: $1.31BFY2025 Cost of revenue: $384M$3.18BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
Annual revenue; bands show net, operating, gross margins · Open in Platform →
Net income for FY2021, FY2022 is the filer’s available-to-common figure (net of preferred dividends) — the filer tags no parent net income for those years.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-20
  • 2026-10-20Chairperson & CEOSale-880$475.0K
  • 2026-10-20Chairperson & CEOSale-160$85.6K
  • 2026-10-20Chairperson & CEOStock OptionOption exercise-9,500—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does United Therapeutics Corporation do?

United Therapeutics is a public benefit corporation founded to develop therapies for serious diseases with unmet medical needs, particularly pulmonary arterial hypertension and rare diseases.

When did UTHR last file with the SEC?

United Therapeutics Corporation's most recent SEC filing on record is a 8-K filed 2026-10-14. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 16:35 UTC. This page is also available as JSON at /api/data?ticker=UTHR and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for UTHR and 5,000+ tickers.

Create a free account — keep UTHR
For your agent
GET /api/data?ticker=UTHR

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt